The core activity of MUGENBIO is the development of biotechnological solutions for the earlier and more accurate diagnosis of cancer, particularly prostate cancer. The company focuses on developing a platform for diagnosing prostate cancer based on three innovative pillars, aiming to improve existing diagnostic methods and enable early detection of prostate cancer.
AI-generated
Offering
Products & services
Industry:Medical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Next-generation diagnostic platform for prostate cancer with ultrasensitive molecular biomarker quantification, a diagnostic device for 100+ biomarkers, and AI data analysis.
Knowledge
No knowledge articles yet
Once MUGENBIO GmbH has claimed this profile, we'll publish editorial articles and case studies here together.